Neuland may defer 134-acre Kakinada site development plans

On November 3, 2026, Neuland Laboratories Limited said development of its approximately 134-acre Kakinada site could be slowed if commercial products are negatively affected, making the land a long-term capacity option rather than near-term production capacity. Neuland said later peptide modules would still be considered when Module 1 is occupied.

Why did Neuland buy land at Kakinada?

Neuland bought approximately 134 acres at Kakinada in Andhra Pradesh during Q2 FY27 to preserve room for future expansion, not to meet an immediate manufacturing requirement. Management said customer discussions are broadening and the types of opportunities are evolving, making it important that infrastructure does not constrain its ability to respond to longer-term capacity requirements.

Management asked investors to assess Kakinada from a long-term return perspective rather than expect immediate returns. It said capacity should be built around customer requirements instead of being added in isolation. That approach reflects Neuland's customer-molecule model, in which clinical progress, customer demand and shipment schedules can change, creating uneven revenue between individual quarters.

Could Neuland defer Kakinada development?

Yes, Neuland said Kakinada is the investment it could defer somewhat if commercial products face a negative impact. Chief Executive Officer Saharsh Davuluri gave that response to an analyst's scenario involving the loss of a major customer, while stressing that management would first judge the short- to medium-term impact on the commercial portfolio.

The company did not announce a construction schedule, development budget or commissioning date for Kakinada. Management instead said it would modulate its move to the site according to conditions. This leaves the approximately 134-acre acquisition as a land-bank option, with the pace of any build-out dependent on commercial demand and customer opportunities.

Neuland also has a nearer-term expansion alternative around Unit I. Management said the board had approved investment to add more land around that existing site, expanding its footprint, although it did not disclose acreage or spending. Davuluri specifically described Kakinada as relatively long term, meaning it sits alongside rather than replaces expansion at Unit I.

Why would peptide expansion continue before Kakinada?

Neuland said peptide Modules 2, 3 and 4 would be triggered if Module 1 is occupied, even if its current commercial business experiences a negative impact. Management said it expects sustained demand for peptide active pharmaceutical ingredients, or APIs, and therefore would not initially hold back the peptide programme under the analyst's hypothetical scenario.

Module 1 was commissioned at Unit One during the first half of FY27 and has shown encouraging traction, according to management. The facility was designed for the requirements of projects already in Neuland's portfolio, including upstream manufacturing equipment, purification columns and lyophilization equipment. Management said later modules would be configured as project visibility develops, rather than follow a fixed equipment template.

The revenue timeline is separate from the decision to retain expansion capacity. Neuland already bills peptide development work, although management described the revenue as not substantial. It expects PPQ, described by management as validation batches, to begin contributing revenue in about six to nine months from the November 3 call, subject to documentation, customer decisions and first-batch shipment timing.

What financial conditions shape the capacity decision?

Neuland reported capital-expenditure outflow of Rs 261 crore for the first half of FY27, free cash flow of Rs 99 crore and net debt of negative Rs 208 crore. Management said investment was progressing in line with plans, but reiterated that both the nature and scale of future capital deployment would be evaluated against customer requirements and available opportunities.

The company gave no separate spending figure for Kakinada, so the Rs 261 crore first-half outflow cannot be assigned to that site. Management's stated capital discipline is relevant because Kakinada has no disclosed build timetable, while Unit I expansion and future peptide modules are also competing for investment attention.

Quarterly earnings also showed the effects of shipment timing and cost pressure. Total income was Rs 457.2 crore in Q2 FY27, compared with Rs 516.1 crore in Q2 FY26, while earnings before interest, tax, depreciation and amortisation, or EBITDA, fell to Rs 104.6 crore from Rs 156.9 crore. EBITDA margin declined to 22.9% from 30.4% over the same comparison.

How does commercial performance affect Neuland's expansion choices?

Neuland said Q2 FY27 revenue was driven predominantly by commercial molecules and products in the Prime portfolio. It attributed quarter-to-quarter variability to the timing and product mix of customer shipments, particularly as individual commercial shipments become larger. Management said there had been no launches in the preceding two or three quarters, with the last launch occurring about a year earlier.

The longer-period comparison was more positive: total income for the first half of FY27 rose to Rs 1,107.2 crore from Rs 816.7 crore in the first half of FY26. Management said the first half was largely in line with its expectations and that growth expectations remained intact for FY27 and the following financial year, despite Q2 moderation.

Costs and working capital remain additional variables in deciding the timing of capacity deployment. Working capital stood at 104 days of sales in Q2 FY27, versus 84 days in the previous quarter. Neuland also cited raw-material volatility and higher freight and logistics costs, and said it would use sourcing strategies, inventory planning and operational efficiencies while monitoring the second half of FY27.

Conclusion

Kakinada gives Neuland approximately 134 acres of long-term expansion flexibility, but management has not committed to a near-term plant build-out. Its comments draw a practical distinction between capacity programmes: peptide modules would be considered once Module 1 is occupied, while Kakinada development could be slowed if commercial products weaken and the short- to medium-term outlook warrants restraint.

Investors should watch whether peptide PPQ-related revenue appears within management's stated six-to-nine-month window, whether Module 1 occupancy supports Modules 2 to 4, and whether commercial shipment timing improves in the second half of FY27. Management also plans to make its new process research and development centre at Genome Valley in Hyderabad fully operational by early next year, while continuing to monitor raw materials, freight and supply-chain conditions.